Compare FTEK & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEK | IXHL |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | United States | Australia |
| Employees | N/A | 12 |
| Industry | Pollution Control Equipment | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 37.0M |
| IPO Year | 1997 | 2024 |
| Metric | FTEK | IXHL |
|---|---|---|
| Price | $1.37 | $2.91 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 187.9K | ★ 204.7K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,467,000.00 | $12,000.00 |
| Revenue This Year | $14.17 | N/A |
| Revenue Next Year | $11.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.16 |
| 52 Week High | $3.64 | $6.39 |
| Indicator | FTEK | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 39.10 | 33.93 |
| Support Level | $1.17 | $2.78 |
| Resistance Level | $1.52 | $3.68 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 0.00 | 12.94 |
Fuel Tech Inc is a technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces, and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling for boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.